on to update any
forward-looking statements contained in this release as a result of new
information, future events or changes in its expectations.
JAZZ PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
Three Months Ended Year Ended
December 31, December 31,
2007 2006 2007 2006
Revenues:
Product sales, net $14,860 $11,890 $53,536 $43,299
Royalties, net 332 258 1,156 594
Contract revenue 285 301 10,611 963
Total revenues 15,477 12,449 65,303 44,856
Operating expenses:
Cost of product sales
(excluding amortization of
acquired developed
technology) 3,283 1,601 8,903 6,968
Research and development 20,540 13,036 69,792 54,956
Selling, general and
administrative 27,958 12,543 78,540 51,384
Intangible asset
amortization 2,280 2,400 9,217 9,600
Intangible asset impairment 20,160 - 20,160 -
Provision for government
settlement - - 17,469 -
Total operating expenses 74,221 29,580 204,081 122,908
Loss from operations (58,744) (17,131) (138,778) (78,052)
Interest income 1,582 619 5,942 2,307
Interest expense (3,554) (3,311) (13,647) (14,129)
Other income (expense)
'/>"/>
SOURCE Jazz Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1.
Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)2.
Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer3.
Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors4.
Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance5.
Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan6.
NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 20077.
Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting8.
Jazz Pharmaceuticals, Inc. Announces Changes to its Board of Directors9.
Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference10.
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT11.
Jazz Pharmaceuticals, Inc. to Announce Third Quarter 2007 Financial Results on November 6, 2007